<DOC>
	<DOCNO>NCT00002632</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness paclitaxel treat patient metastatic recurrent salivary gland cancer .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Metastatic Recurrent Salivary Gland Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate response rate patient metastatic recurrent salivary gland cancer treat paclitaxel ( Taxol , TAX ) 3-hour infusion . II . Describe toxicity TAX patient . OUTLINE : Single-Agent Chemotherapy . Paclitaxel ( Bristol-Myers ) , Taxol , TAX , NSC-125973 . PROJECTED ACCRUAL : Up 32 patients/histology enter . If response observe first 14 patient particular histology , accrual group close ; 18 month annual accrual less 10 patients/histology , accrual group may close .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm salivary gland carcinoma metastatic recurrent , include follow type : Mucoepidermoid carcinoma Adenocarcinoma Pathology review require Measurable disease require Lesion previously irradiate field must progress biopsy proven PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Hematopoietic : WBC least 3,000/mm3 ANC least 1,500/mm3 Platelet count least 100,000/mm3 Hb least 10 g/dL Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : No MI within past 6 month No CHF No unstable arrhythmia No current antiarrhythmic , inotropic , antianginal medication Other : No history allergy Cremophor No prior malignancy within 5 year except : Curatively treat nonmelanomatous skin cancer Curatively treat insitu cancer cervix No concurrent malignancy Not pregnant nursing Effective contraception strongly advise fertile patient Blood/body fluid analyse determine eligibility image study scans/xrays tumor measurement complete within 14 day prior registration PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biological response modifier therapy allow Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow recovery Surgery : Prior surgery allow recovery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>high-grade salivary gland mucoepidermoid carcinoma</keyword>
	<keyword>salivary gland adenocarcinoma</keyword>
</DOC>